Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 4/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24016459 | 0.85 | MTNR1A (0.56) | DAOATAD2PRMT5WDR77MTNR1A | |
| SCHEMBL30759248 | 0.84 | BCHE (0.49) | DAOATAD2PRMT5WDR77MTNR1A | |
| SCHEMBL27144888 | 0.83 | DAO (0.48) | DAOATAD2PRMT5WDR77MTNR1A | |
| SCHEMBL29865238 | 0.77 | ATAD2 (0.49) | DAOATAD2PRMT5WDR77MTNR1A | |
| SCHEMBL18307631 | 0.73 | MAPT (0.48) | MAPTKDM4EPTGESHDAC6 | |
| SCHEMBL3429551 | 0.73 | DAO (0.51) | DAOATAD2PRMT5WDR77HRH4 | |
| SCHEMBL30040118 | 0.72 | DAO (0.53) | DAOATAD2PRMT5WDR77HRH4 | |
| SCHEMBL9396748 | 0.72 | DAO (0.53) | DAOATAD2PRMT5WDR77HRH4 | |
| SCHEMBL12677225 | 0.72 | ATAD2 (0.53) | DAOATAD2HRH4NR3C1MAPT | |
| SCHEMBL10410419 | 0.72 | DAO (0.50) | DAOATAD2PRMT5WDR77HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | DAO 3654/4885ATAD2 1075/4885PRMT5 1041/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | DAO 3464/4885ATAD2 990/4885PRMT5 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.